Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

Also called NCT07720232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Jianyin Zhou (from the registry)
Registry
  • NCT NCT07720232
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07720232. Randomized; double masking; primary purpose treatment. Start 2026-01-18 (actual); primary completion 2028-01-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
Condition
Hypertriglyceridemic Acute Pancreatitis
Condition
Acute Pancreatitis, Hypertriglyceridemia-induced
Condition
Hyperlipidemia
Intervention (Drug)
Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE)
Intervention (Drug)
Standard Care (in control arm)
Lead sponsor
Jianyin Zhou (class: other)

Record details

Record id
cardio:ct-nct07720232
Content hash
fbf090ba90457399e6dea6d6519ac09ca8e48f3bcf30dc05223740d4eb12b7f7